Drugs firm Elan is to embark on a new corporate strategy, marking a departure from conducting its business on a traditional sales commercial model. As part of the Athlone-based firm’s “realignment” of its business, it is to close offices in New York and Tokyo, "eliminate" a number of positions and alter its strategy for marketing its flagship Tysabri drug. The restructuring comes after months of assessing several options to ensure sufficient resources are directed toward its most promising research and development opportunities, according to chief executive Kelly Martin.
Elan president Carlos V. Paya said that Elan would shift its effort from what is a traditional sales commercial model to a model based on clinical support and education.
Meanwhile, Elan has confirmed another case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient being treated with its Tysabri drug in Europe. Tysabri was withdrawn from the market in February 2005 after two patients died after contracting PML and reintroduced in 2006. http://www.elan.com
Using the buttons below you can save this article to your favourite social bookmarking site